stockrowLantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.
- Revenue
- +1.54%
- EPS
- −17.1%
- Free cash flow
- +7.71%
- Total debt
- +0.52%
Quarter to September 2026, against a year earlier
Follow LNTH
Alert me
Lantheus Holdings, Inc. (LNTH) Net income
Lantheus Holdings, Inc.'s net income for fiscal 2025 was $233.6M, down 25.2% from $312.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $269.9M. Over the past ten years it has ranged from −$71.3M (fiscal 2021) to $326.7M (fiscal 2023); the current reading is higher than 82% of that period. Lantheus Holdings, Inc. ranks 10th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $233.6M | (25.25%) |
| FY2024 | $312.4M | (4.35%) |
| FY2023 | $326.7M | 1,063.86% |
| FY2022 | $28.1M | — |
| FY2021 | −$71.3M | — |
| FY2020 | −$13.5M | — |
| FY2019 | $31.7M | (21.84%) |
| FY2018 | $40.5M | (67.16%) |
| FY2017 | $123.4M | 361.05% |
| FY2016 | $26.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $22.4M | (70.18%) |
| Jun 2026 | $75.0M | (36.64%) |
| Mar 2026 | $118.4M | 118.93% |
| Dec 2025 | $54.1M | 94.76% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. compare | $450.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| LNTH Lantheus Holdings, Inc. | $269.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $209.5M |
| LQDA Liquidia Corporation compare | $138.6M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $109.6M |
| ALKS Alkermes plc compare | −$351.0K |
| HIMS Hims & Hers Health, Inc. compare | −$142.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$152.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on LNTH
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement